Lubrizol acquires German medical device maker Bavaria Medizin

Lubrizol acquires German medical device maker Bavaria Medizin

6:32 AM, 17th July 2019
Bavaria Medizin is an innovative designer and manufacturer of both intravascular and nonvascular devices, including drug-coated balloons.
Bavaria Medizin is an innovative designer and manufacturer of both intravascular and nonvascular devices, including drug-coated balloons.

CLEVELAND, US: The Lubrizol Corporation has acquired Bavaria Medizin Technologie GmbH (BMT), an innovative designer and manufacturer of both intravascular (coronary, peripheral, and cranial) and nonvascular devices, including drug-coated balloons.

This acquisition builds upon Lubrizol’s expertise in precision thermoplastic extrusion and product development, establishing Lubrizol as a true end-to-end partner to the global medical device and pharmaceutical industries. 

With over 100 employees, BMT is headquartered near Munich, Germany and operates a manufacturing facility in Sibiu, Romania. A pioneer in catheter-based technologies, BMT developed the first commercial drug-coated balloon, the Paccocath catheter.

Today, BMT holds over 50 patents and continues to innovate through self-funded R&D projects, as well as contract R&D services. Additionally, BMT offers private label manufacturing of proprietary catheters and balloons along with original equipment manufacturing (OEM) services, which include the manufacturing of subassemblies and components, sterilization, packaging and labeling, stent crimping, and logistics management.

The acquisition of BMT expands Lubrizol’s product design, development, and manufacturing expertise and provides access to proprietary catheter and balloon technologies. BMT’s experience and reputation in the drug-coated balloon (DCB) space aligns well with Lubrizol’s pharmaceutical CDMO business and positions Lubrizol as the ideal partner for developing next generation DCBs.

“Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space. Our customers will benefit from additional design capabilities, an increased global footprint, and synergies with our existing formulation and manufacturing services,” said Uwe Winzen, general manager of the Health business of Lubrizol Life Science.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Aquatech China: Opportunities in the Chinese water market continue to grow

Aquatech China 2019 was a winning mix of business, content and international networking. This 12th edition of Aquatech China turned out even more powe ...

Read more
Nouryon doubles dicumyl peroxide capacity in China

AMSTERDAM, NETHERLANDS: Nouryon has doubled production capacity for dicumyl peroxide (DCP) at its site in Ningbo, China after completing a major expan ...

Read more
Entegris acquires MPD Chemicals for $165 million

BILLERICA, US: Entegris Inc has acquired MPD Chemicals, a provider of advanced materials to the specialty chemical, technology, and life sciences indu ...

Read more
GlaxoSmithKline gets EC approval to buy Pfizer's consumer health biz

BRUSSELS, BELGIUM: The European Commission has approved the acquisition of Pfizer's consumer health business by GlaxoSmithKline (GSK). The decision is ...

Read more
OMV plans to build €64 mn high-purity isobutene plant in Germany

VIENNA, AUSTRIA: OMV AG has decided to invest €64 million in the construction of an ISO C4 plant at Burghausen Refinery, Germany. OMV is an inter ...

Read more
DuPont opens world-class probiotics fermentation unit in New York

ROCHESTER, US: DuPont has opened a new state-of-the-art probiotics fermentation unit at its Rochester, New York, facility. Construction of the unit wa ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X